Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE).

Trial Profile

Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Icatibant (Primary) ; Tranexamic acid
  • Indications Hereditary angioedema
  • Focus Therapeutic Use
  • Acronyms FAST-2
  • Sponsors Shire
  • Most Recent Events

    • 12 Sep 2013 Results published in Allergy.
    • 08 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top